There is a growing consensus among scientists that fulfilling the promise of molecular medicine requires a shift from the study of single events to viewing complex biological systems in their entirety. CRi’s integrated imaging products provide researchers and clinicians with quantitative assessments of disease and drug response. This is accomplished by evaluating multiple markers simultaneously in intact tissue samples, at a cellular level or in living small animals. CRi’s solutions have received strong industry recognition for having a significant impact in translational and clinical research and applications.
“The acceptance of CRi solutions by the world’s leading pharmaceutical companies further establishes the trend for drug development efforts, particularly in areas such as oncology, to focus on developing targeted therapies for more molecularly defined patient populations,” said George Abe, chief executive officer at CRi. “Researchers realize the significant capabilities of CRi’s platform technology and the efficiency and productivity gains that they provide, along with the potential to translate into diagnostic applications.”
CRi’s diverse and applications-focused products have revolutionized fluorescence and brightfield microscopy, in vivo imaging and assisted reproductive technologies. Based on its proprietary technology, CRi systems enable researchers to better explore biological pathways in drug development and personalized medicine by bridging the gap between combinatorial chemistry, flow cytometry and morphological imaging